Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-small Cell Lung Cancer Metastatic 1

Interventions

tusamitamab ravtansine 2Ramucirumab 2Docetaxel 2telomerase reverse transcriptase p572Y, human 1pembrolizumab 1necitumumab 1Paclitaxel 1LY3023414 1Gemcitabine 1Erlotinib Hydrochloride 1Data Collection 1Carboplatin 1Bevacizumab 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-small Cell Lung Cancer Metastatic × telomerase reverse transcriptase p572Y, human × Clear all
NCT01935154 2019-06-19

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Vaxon Biotech

Phase 2 Completed
221 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡